Su Lu, Dalby Kellie S, Luehmann Hannah, Elkassih Sussana A, Cho Sangho, He Xun, Detering Lisa, Lin Yen-Nan, Kang Nari, Moore Dennis A, Laforest Richard, Sun Guorong, Liu Yongjian, Wooley Karen L
Department of Chemistry, Department of Materials Science and Engineering, and Department of Chemical Engineering, Texas A&M University, College Station, TX 77842, USA.
Laboratory of Macromolecular and Organic Chemistry and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, MB 5600, The Netherlands.
Acta Pharm Sin B. 2023 Apr;13(4):1660-1670. doi: 10.1016/j.apsb.2022.09.009. Epub 2022 Sep 16.
To expand the single-dose duration over which noninvasive clinical and preclinical cancer imaging can be conducted with high sensitivity, and well-defined spatial and temporal resolutions, a facile strategy to prepare ultrasmall nanoparticulate X-ray contrast media (nano-XRCM) as dual-modality imaging agents for positron emission tomography (PET) and computed tomography (CT) has been established. Synthesized from controlled copolymerization of triiodobenzoyl ethyl acrylate and oligo(ethylene oxide) acrylate monomers, the amphiphilic statistical iodocopolymers (ICPs) could directly dissolve in water to afford thermodynamically stable solutions with high aqueous iodine concentrations (>140 mg iodine/mL water) and comparable viscosities to conventional small molecule XRCM. The formation of ultrasmall iodinated nanoparticles with hydrodynamic diameters of 10 nm in water was confirmed by dynamic and static light scattering techniques. In a breast cancer mouse model, biodistribution studies revealed that the Cu-chelator-functionalized iodinated nano-XRCM exhibited extended blood residency and higher tumor accumulation compared to typical small molecule imaging agents. PET/CT imaging of tumor over 3 days showed good correlation between PET and CT signals, while CT imaging allowed continuous observation of tumor retention even after 10 days post-injection, enabling longitudinal monitoring of tumor retention for imaging or potentially therapeutic effect after a single administration of nano-XRCM.
为了延长单剂量给药的持续时间,在此期间能够以高灵敏度以及明确的空间和时间分辨率进行非侵入性临床和临床前癌症成像,已建立了一种简便的策略来制备超小纳米颗粒X射线造影剂(nano-XRCM),作为正电子发射断层扫描(PET)和计算机断层扫描(CT)的双模态成像剂。由三碘苯甲酰丙烯酸乙酯和聚环氧乙烷丙烯酸酯单体通过可控共聚合成的两亲性统计碘共聚物(ICP)可直接溶于水,形成热力学稳定的溶液,具有高水碘浓度(>140 mg碘/ mL水),且粘度与传统小分子XRCM相当。通过动态和静态光散射技术证实了在水中形成了流体动力学直径为10 nm的超小碘化纳米颗粒。在乳腺癌小鼠模型中,生物分布研究表明,与典型的小分子成像剂相比,铜螯合剂功能化的碘化nano-XRCM具有更长的血液驻留时间和更高的肿瘤蓄积量。对肿瘤进行3天的PET/CT成像显示PET和CT信号之间具有良好的相关性,而CT成像即使在注射后10天仍能持续观察到肿瘤滞留情况,从而能够在单次给予nano-XRCM后对肿瘤滞留情况进行纵向监测,用于成像或潜在的治疗效果评估。